ADAMTS13 gene
ADAM metallopeptidase with thrombospondin type 1 motif 13
The ADAMTS13 gene provides instructions for making an enzyme that is involved in blood clotting. After an injury, clots normally protect the body by sealing off damaged blood vessels and preventing further blood loss.
The ADAMTS13 enzyme processes a large protein called von Willebrand factor, which also plays a role in clot formation. The unprocessed form of von Willebrand factor interacts easily with cells called platelets, which circulate in the bloodstream and are essential for blood clotting. The factor helps platelets stick together and adhere to the walls of blood vessels, forming temporary clots. The ADAMTS13 enzyme cuts von Willebrand factor into smaller pieces. By processing von Willebrand factor in this way, the enzyme prevents it from triggering the formation of unnecessary blood clots.
Related Information
More than 70 mutations in the ADAMTS13 gene have been reported in people with the familial form of thrombotic thrombocytopenic purpura. Most of these mutations change single protein building blocks (amino acids) in the ADAMTS13 enzyme. Other mutations lead to the production of an abnormally small version of the enzyme that cannot function properly.
Mutations in the ADAMTS13 gene severely reduce the activity of the ADAMTS13 enzyme. As a result, von Willebrand factor is not processed normally in the bloodstream. If the factor is not cut into smaller fragments by the ADAMTS13 enzyme, it promotes the formation of abnormal clots throughout the body. The large, uncut version of von Willebrand factor induces platelets to stick together and adhere to the walls of blood vessels, even in the absence of injury. Additional factors such as pregnancy, diarrhea, surgery, and infection likely play a role in triggering abnormal clotting. Blood clots can block blood flow through small vessels, causing damage to the brain, kidneys, heart, and other organs. Abnormal clotting also causes other complications associated with thrombotic thrombocytopenic purpura.
Related Information
Cytogenetic Location: 9q34.2, which is the long (q) arm of chromosome 9 at position 34.2
Molecular Location: base pairs 133,414,339 to 133,459,403 on chromosome 9 (Homo sapiens Updated Annotation Release 109.20191205, GRCh38.p13) (NCBI)
Related Information
- ADAM metallopeptidase with thrombospondin type 1 motif, 13
- ADAMTS-13
- ATS13_HUMAN
- C9orf8
- von Willebrand factor-cleaving protease
- vWF-cleaving protease
- vWF-CP
- VWFCP
Related Information
- Bowen DJ, Collins PW. Insights into von Willebrand factor proteolysis: clinical implications. Br J Haematol. 2006 Jun;133(5):457-67. Review.
- Dong JF. Cleavage of ultra-large von Willebrand factor by ADAMTS-13 under flow conditions. J Thromb Haemost. 2005 Aug;3(8):1710-6. Review.
- Kremer Hovinga JA, Studt JD, Lämmle B. The von Willebrand factor-cleaving protease (ADAMTS-13) and the diagnosis of thrombotic thrombocytopenic purpura (TTP). Pathophysiol Haemost Thromb. 2003 Sep-2004 Dec;33(5-6):417-21. Review.
- Levy GG, Motto DG, Ginsburg D. ADAMTS13 turns 3. Blood. 2005 Jul 1;106(1):11-7. Epub 2005 Mar 17. Review.
- Levy GG, Nichols WC, Lian EC, Foroud T, McClintick JN, McGee BM, Yang AY, Siemieniak DR, Stark KR, Gruppo R, Sarode R, Shurin SB, Chandrasekaran V, Stabler SP, Sabio H, Bouhassira EE, Upshaw JD Jr, Ginsburg D, Tsai HM. Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura. Nature. 2001 Oct 4;413(6855):488-94.
- Sadler JE, Moake JL, Miyata T, George JN. Recent advances in thrombotic thrombocytopenic purpura. Hematology Am Soc Hematol Educ Program. 2004:407-23. Review.
- Tsai HM. Advances in the pathogenesis, diagnosis, and treatment of thrombotic thrombocytopenic purpura. J Am Soc Nephrol. 2003 Apr;14(4):1072-81. Review.
- Tsai HM. Current concepts in thrombotic thrombocytopenic purpura. Annu Rev Med. 2006;57:419-36. Review.
- Tsai HM. Is severe deficiency of ADAMTS-13 specific for thrombotic thrombocytopenic purpura? Yes. J Thromb Haemost. 2003 Apr;1(4):625-31. Review.
- Tsai HM. Molecular mechanisms in thrombotic thrombocytopenic purpura. Semin Thromb Hemost. 2004 Oct;30(5):549-57. Review.
- Tsai HM. The molecular biology of thrombotic microangiopathy. Kidney Int. 2006 Jul;70(1):16-23. Epub 2006 May 31. Review.
- Tsai HM. Thrombotic thrombocytopenic purpura: a thrombotic disorder caused by ADAMTS13 deficiency. Hematol Oncol Clin North Am. 2007 Aug;21(4):609-32, v. Review.
- Wilkinson R. People have been at work a long time. Nurs Manage. 1991 Dec;22(12):38-9.
- Wolf G. Not known from ADAM(TS-13)--novel insights into the pathophysiology of thrombotic microangiopathies. Nephrol Dial Transplant. 2004 Jul;19(7):1687-93. Epub 2004 May 5. Review.
- Yarranton H, Machin SJ. An update on the pathogenesis and management of acquired thrombotic thrombocytopenic purpura. Curr Opin Neurol. 2003 Jun;16(3):367-73. Review.